Understanding how certain proteins affect cancer treatment resistance
Official title: Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance
Funded at Wright State University · NIH-10996158 · Data updated 2026-11-12
This study is looking at how certain proteins might affect the growth of squamous cell carcinoma and why some patients don’t respond well to the chemotherapy drug cisplatin, with the hope of finding better treatment options for those who struggle with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project start | December 7, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $610,770 |
| NIH project number | 5R01CA280075-02 |
| Project ID | NIH-10996158 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with squamous cell carcinoma who have experienced resistance to cisplatin treatment.
✕Less likely to help
Patients with non-squamous cell carcinoma types or those who have not undergone cisplatin treatment may not benefit from this research.
What this research studies
This research investigates the role of specific proteins, DeltaNp63 alpha and TIP60, in the progression of squamous cell carcinoma (SCC) and their contribution to resistance against the chemotherapy drug cisplatin. By examining how these proteins interact and influence cancer cell behavior, the research aims to uncover new mechanisms that lead to treatment failure. Patients may benefit from this work as it could lead to improved treatment strategies for those whose cancers do not respond to current therapies. The study employs biological models and cell line experiments to explore these interactions and their implications for cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with chemoresistant squamous cell carcinoma.
How similar studies have gone: Previous research has shown promising results in understanding cancer resistance mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Wright State University
Dayton, United States Active
Researchers
- Principal investigator: Kadakia, Madhavi P — Wright State University
- Study coordinator: Kadakia, Madhavi P
Related research
Other NIH-funded projects on the same topics.
-
Excitability dysfunction in ALS and FTD linked to TDP-43
A patient-focused research opportunity to understand how nerve cell electrical activity goes wrong in ALS and related dementia linked to TDP-43.
-
Glycosylation changes that boost heart signals and lead to heart failure
A study to understand how changes in sugar attachments on heart cell receptors may fuel heart failure, with potential to guide new treatments.
-
Regulation of TRPM7 in low and high magnesium conditions
This grant studies how the TRPM7 ion channel and enzyme influence immune cell function when magnesium levels change, which could affect immune responses in people.
-
Lipin1 and Micro-Dystrophin Gene Therapies for DMD: A New Dual Approach
A study to explore whether boosting Lipin1 together with micro-dystrophin gene therapy could improve muscle and heart health in Duchenne muscular dystrophy patients.
-
Neuromuscular Junction Problems in Hyperkalemic Paralysis
A clinician-scientist is pursuing five years of advanced training and research to better understand and care for people with neuromuscular diseases related to hyperkalemic paralysis.
-
Understanding why nerve cells in ALS and FTD misfire and how to help them
Aims to understand why motor neurons become over- or under-responsive in ALS and related brain disorders using a mouse model that mimics human disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.